Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Bryce on Ongoing Research Regarding CDK12 Alterations in Prostate Cancer

January 30th 2020

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Dr. Shinohara on Toxicities of Stereotactic Body Radiotherapy in Prostate Cancer

January 30th 2020

Eric Shinohara, MD, MSCI, discusses the toxicities associated with stereotactic body radiotherapy in prostate cancer.

Dr. Oh on the ENZAMET Trial in mHSPC

January 30th 2020

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Apalutamide Approved in Europe for Metastatic Castration-Sensitive Prostate Cancer

January 29th 2020

The European Commission has approved apalutamide for use in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer.

Radiopharmaceuticals Show Signs of Progress in Prostate Cancer

January 29th 2020

A. Oliver Sartor, MD, discusses the development of radiopharmaceuticals in prostate cancer.

Dr. Koo on the Actionability of Next-Generation Imaging Results in Prostate Cancer

January 29th 2020

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the actionability of next-generation imaging results in prostate cancer.

Dr. Bryce on Ongoing Research in Prostate Cancer

January 29th 2020

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

Dr. Hwang on the State of Treatment in Metastatic Prostate Cancer

January 29th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

Dr. Moses On Ongoing Trials in mHSPC

January 28th 2020

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Dr. Penson on Maintaining QoL With AR Inhibitors in Nonmetastatic CRPC

January 25th 2020

David F. Penson, MD, MPH, MMHC, discusses the importance of maintaining quality of life for patients treated with androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.

Dr. Cheng on Molecular Testing Considerations in Prostate Cancer

January 25th 2020

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Dr. Shinohara on the Future of Radiation and Surgery in Prostate Cancer

January 25th 2020

Eric Shinohara, MD, MSCI, discusses the future of stereotactic body radiation and surgery in prostate cancer.

Dr. Sartor on Promising Treatment Approaches in Prostate Cancer

January 25th 2020

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

Dr. Penson on Questions Regarding Next-Generation AR Inhibitors in Prostate Cancer

January 25th 2020

David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.

Dr. Kohli on Drugs That Have Been Evaluated in mCRPC

January 25th 2020

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Dr. Hwang on Treatment Selection in Metastatic Castration-Sensitive Prostate Cancer

January 24th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Dr. Paulson on Molecular Testing in Oncology

January 24th 2020

R. Steven Paulson, MD, discusses molecular testing in oncology.

Dr. Heath on Remaining Challenges in Nonmetastatic CRPC

January 23rd 2020

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.

Dr. Koo on Metastasis-Directed Therapy in Prostate Cancer

January 21st 2020

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the use of metastasis-directed therapy in prostate cancer.

FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC

January 21st 2020

The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.